Vitalgenics

Vitalgenics is a private U.S. oncology-focused biopharmaceutical company centered on pancreatic cancer, especially pancreatic ductal adenocarcinoma. Publicly available descriptions portray the company as developing Excindogen, described as an FDA-repurposed immunotherapy/small-molecule program for pancreatic cancer, with a locoregional delivery strategy that may use a dual-balloon catheter for tumor-site administration. The company presents itself as "etiology-centric," emphasizing disease-cause biology as the basis for therapeutic design and pipeline generation. Third-party sources indicate orphan-drug-related positioning in pancreatic cancer and characterize the company as clinical stage, but the company appears to have limited recent verifiable operating disclosures and its Colorado corporate registration has been listed as delinquent. Overall, Vitalgenics appears to be a small, private pancreatic cancer biotech with one disclosed lead program and sparse independently verified pipeline detail.